IL-SANG YOON

IL-SANG YOON has worked in a variety of roles across multiple companies since 2001. In 2001, they began as an Assistant Project Scientist/Post-doc at UC San Diego, where they investigated potential roles of proteins in Alzheimer's Disease. From 2008 to 2009, they were a Research Scientist II at CytRx Corporation, where they developed high throughput screening to identify inhibitors for HSF1, developed cell-based assays for oxidative stress, and was involved in MOA studies for CytRx clinical candidate compounds. From 2009 to 2011, they were a Principal Scientist at MabPrex, Inc. From 2011 to 2013, they were a Senior Scientist at Nexus Dx, where they were involved in IVD product development, Lateral flow immunoassay, Cardiac protein biomarkers, Microfluidic-based and analogous diagnostic devices development, antibody conjugation, and quantitative immuno assay development. From 2013 to 2016, they were Managing Director and Associate Director at SD Medical System Inc. From 2020 to 2022, they were Senior Vice President, Head of R&D center at PharmCADD, an AI & Physics-based drug discovery company located in Seoul & Busan, South Korea. Currently, they are the Chief Alliance Officer at BIORCHESTRA Co., Ltd.

IL-Sang Yoon obtained a Ph.D in Gene expression profiling in Psychiatric disorders from the University of Toronto, an M.Sc. in Clinical Biochemistry from the University of Toronto, and a B.Sc. in Biochemistry from Yonsei University.